TGA Internet site archive

The content on this page and other TGA archive pages is provided to assist research and may contain references to activities or policies that have no current application. See the full archive disclaimer.

Expert Committee on Complementary Medicines in the Health System

Background

The supply of safe, high quality and efficacious complementary medicines, the quality use of and timely access to these medicines and the maintenance of a responsible and viable complementary medicines industry are important objectives for Governments, healthcare practitioners, consumers and industry.

In April 2003, the Therapeutic Goods Administration initiated the recall of more than 1600 complementary medicines from the Australian marketplace. It was the largest recall of medicines in Australia and heightened interest in complementary medicines. The recall was a result of the failure of one medicine manufacturer to maintain appropriate manufacturing and quality control standards.

Following the recall, consumer groups, health professionals, researchers and practitioners raised concerns regarding the level of trust that can be placed in complementary medicines. These concerns included doubts about the reliance consumers may have in the information available about complementary medicines and confidence in their effectiveness. The role of complementary healthcare practitioners also came under scrutiny. The level of education and training of practitioners, lack of qualification and registration requirements, and the variability of regulation across jurisdictions, raised questions about the extent to which the community can depend on their expertise and advice.

In May 2003, to reassure the public and maintain confidence in Australia's reputation as a supplier of high quality and safe medicines, the Australian Government established the Expert Committee on Complementary Medicines in the Health System (the Expert Committee).

Expert committee terms of reference

The Expert Committee was asked to consider the regulatory, health system and industry structures necessary to ensure that the central objectives of the National Medicines Policy are met in relation to complementary medicines.

The Expert Committee was also asked to examine and provide advice on:

  • The national system of regulatory controls required to ensure that complementary medicines meet appropriate standards of quality, safety and efficacy;
  • The information needs of consumers of complementary medicines;
  • The education, training, and regulation requirements for healthcare practitioners who are supplying complementary medicines and/or providing advice or delivering care to consumers of complementary medicines;
  • The potential for interaction between complementary medicines and prescribed medicines used by consumers and the means to provide this information to healthcare practitioners;
  • The nature and extent of restrictions required on advertising (including internet advertising) of complementary medicines to consumers; and
  • The regulatory and industry activities necessary to promote an innovative, responsible and viable complementary medicines industry in Australia.

Expert committee membership

Members of the Expert Committee were selected on the basis of their expertise in various areas of complementary medicine, not as representatives of stakeholder groups.

The Government decision to include these members in the Expert Committee was made on the basis that they were considered to have the appropriate depth and breadth of expertise to consider matters under the Expert Committee's terms of reference.

The names of members of the Expert Committee, their affiliation and expertise are listed in the following table:

Name Affiliation Expertise
Dr Michael Bollen (Chair) Former member of the National Health and Medical Research Council (NHMRC)
Principal, BMP Healthcare Consulting Pty Ltd
Quality use of medicines, healthcare delivery, consumer medicines information and general medical practice
Dr John Aloizos Chair, Australian Pharmaceutical Advisory Council (APAC) Implementation of all aspects of National Medicines Policy and general medical practice
Associate Professor Alan Bensoussan Centre for Complementary Medicine Research, University of Western Sydney
Member, Expert Advisory Panel to Complementary Medicines Evaluation Committee (CMEC)
Use and evaluation of complementary medicines and therapies in clinical practice; practitioner education and training
Dr Kerry Breen Chair, NHMRC Australian Health Ethics Committee Ethical issues associated with the promotion and use of medicines
Professor Terry Campbell Head, UNSW Department of Medicine, St Vincent's Clinical School, Sydney
Member, Pharmaceutical Benefits Advisory Committee (PBAC)
Clinical pharmacology
Mr Philip Daffy Consultant to the complementary medicines industry, including the Complementary Healthcare Council of Australia (CHC) Product development complementary medicines
Dr Paul Dugdale Chief Health Officer,
ACT Department of Health
State and Territory issues associated with practitioner regulation, regulation of dispensed and extemporaneously compounded complementary medicines
Associate Professor John Eden University of New South Wales,
School of Women's and Children's Health
Use of complementary medicines and therapies in medical practice, particularly in women's health
Mr Ross Johnston Vice President Manufacturing Operations Asia Pacific, Wyeth Quality assurance in the manufacture of complementary, OTC and prescription medicines
Professor Alastair MacLennan Department of Obstetrics and Gynaecology, University of Adelaide Complementary medicine epidemiology and safety of complementary medicines
Mr David McLeod Naturopath, Fellow with the Australian acupuncture and Chinese Medicine Association Use of complementary medicines in complementary medicine practice; practitioner education and training
Professor Stephen Myers Director, Australian Centre for Complementary Medicine Education and Research, Southern Cross University/University of Queensland, Member of CMEC Use and evaluation of complementary medicines in medical practice; practitioner education and training
Mr Anthony Nunan Principal - Parade Pharmacy; Nunan's Watsonia Pharmacy; Heath's Road Medical Clinic Pharmacy
Chairman - Australian Medicines Handbook
Small business issues; quality use of medicines; postgraduate pharmacist education and training; pharmacy
Ms Juliet Seifert Executive Director,
Australian Self-Medication Industry (ASMI)
Quality use of medicines and industry issues, including complementary medicines
Associate Professor Anne Tonkin Department of Clinical and Experimental Pharmacology University of Adelaide,
Former Chair of CMEC
Evaluation of efficacy and clinical pharmacology, medical education
Mr Darin Walters Chief Executive Officer,
Blackmores Ltd
Complementary medicines industry
Professor Bill Webster Head, Department of Anatomy and Histology, University of Sydney
Member of CMEC
Toxicology and the safety of complementary medicines
Associate Professor Heather Yeatman Head, Graduate School of Public Health, University of Wollongong
Member of CMEC
Member, Food Standards Australia New Zealand (FSANZ) Board
Consumer issues associated with the use of complementary medicines, food and nutrition

Top of page

Media releases

These links are to media releases on the Australian Government Department of Health and Ageing website <http://www.health.gov.au>.

Reports

Top of page